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Summary
Degeneration of basal forebrain cholinergic neurons
(BFCNs) contributes to cognitive dysfunction in Alz-
heimer’s disease (AD) and Down’s syndrome (DS).
We used Ts65Dn and Ts1Cje mouse models of DS to
show that the increased dose of the amyloid precursor
protein gene, App, acts to markedly decrease NGF ret-
rograde transport and cause degeneration of BFCNs.
NGF transport was also decreased in mice expressing
wild-type human APP or a familial AD-linked mutant
APP; while significant, the decreases were less marked
and there was no evident degeneration of BFCNs. Be-
cause of evidence suggesting that the NGF transport
defect was intra-axonal, we explored within choliner-
gic axons the status of early endosomes (EEs). NGF-
containing EEs were enlarged in Ts65Dn mice and their
App content was increased. Our study thus provides
evidence for a pathogenic mechanism for DS in which
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10 Present address: European Brain Research Institute, Rita Levi-
Montalcini Foundation, 00143 Rome, Italy.increased expression of App, in the context of trisomy,
causes abnormal transport of NGF and cholinergic
neurodegeneration.
Introduction
Alzheimer’s disease (AD) is a dementing disorder that
features the dysfunction and degeneration of specific
neuronal populations (Cummings, 2004). Virtually all el-
derly people with Down’s syndrome (DS), trisomy 21,
show neuropathological features of AD (Wisniewski
et al., 1985) and many show cognitive decline (Lai and
Williams, 1989). Although the pathogenesis of DS-re-
lated neurodegeneration is poorly defined, the presence
of one extra copy of one or more normal genes or regu-
latory sequences on chromosome 21 must be responsi-
ble. Establishing links between overexpression of these
genes and AD-related phenotypes in DS will inform the
pathogenesis of DS and AD.
Atrophy and loss of basal forebrain cholinergic neu-
rons (BFCNs), a phenotype seen in AD, DS (Mann
et al., 1985; Whitehouse et al., 1981), and several other
neurodegenerative disorders (see Salehi et al., 1994),
likely contributes to cognitive decline (Auld et al., 2002)
but is poorly understood. To elucidate pathogenesis,
we examined BFCN degeneration in Ts65Dn mice which
are segmentally trisomic for mouse chromosome 16
(Davisson et al., 1990) and show features of DS (Beli-
chenko et al., 2004; Cooper et al., 2001; Kleschevnikov
et al., 2004). The trisomic segment contains about 140
genes with homologs on human chromosome 21 in a re-
gion associated with many DS abnormalities (Korenberg
et al., 1994). The Ts65Dn mouse shows age-related atro-
phy and loss of BFCNs in the medial septal nucleus
(MSN) as measured using immunostaining for either
p75NTR (p75NTR-Ir) or choline acetyltransferase (ChAT-
Ir) (Cooper et al., 2001; Holtzman et al., 1996; Seo and
Isacson, 2005). p75NTR has been extensively used to
characterize these neurons (Jaffar et al., 2001). On the
basis of earlier findings, we postulated that degenera-
tion is due to the demonstrated failure of retrograde
transport of nerve growth factor (NGF). NGF is a tar-
get-derived neurotrophic factor that acts through its
specific receptors, TrkA and p75NTR, to enhance the sur-
vival, differentiation, and maintenance of specific neu-
rons of the peripheral and central nervous systems (Ye
et al., 2003), including BFCNs (Sofroniew et al., 2001).
In mature neurons, NGF signaling regulates expression
of genes important for neuronal phenotype and cell
size. The source of NGF for BFCNs in the MSN is the hip-
pocampus; NGF produced in hippocampus binds to re-
ceptors on BFCN axons and, following endocytosis, is
retrogradely transported to cell bodies (Sofroniew
et al., 2001). Speaking to the importance of NGF for ma-
ture BFCNs, transgenic (Tg) mice that produce anti-
bodies to NGF show severe age-related BFCN degener-
ation (Capsoni et al., 2000). Of note, we showed that the
decrease in the number of BFCNs in Ts65Dn mice was
not due to the death of these neurons, but rather to
the downregulation of p75NTR gene expression, which
Neuron
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bypassing the NGF transport defect through delivery of
NGF to cell bodies by intracerebroventricular injection
reversed deficits in BFCNs (Cooper et al., 2001). Herein,
we provide evidence of a role for increased App gene
dose and expression in causing the defect in NGF trans-
port and the degeneration of BFCNs in the Ts65Dn
mouse.
Results
Examining NGF Transport and BFCNs in Mouse
Models of DS
To explore the mechanism of decreased NGF transport
and its significance for degeneration of BFCNs, we used
genetic models of DS: (1) Ts65Dn mice segmentally tri-
somic for chromosome 16; (2) Ts1Cje mice (Sago
et al., 1998) segmentally trisomic for w100 of the 140
genes present in Ts65Dn; and (3) Ts65Dn mice in which
the third copy of App was deleted. To examine retro-
grade transport of NGF in BFCNs, we injected radiola-
beled NGF into the hippocampus of control (2N = dip-
loid) and Ts65Dn mice and measured radioactivity in
septum 12 hr later. Transport was severely reduced in
Ts65Dn mice relative to the controls (Figure 1A). Mea-
surements at regular intervals for 24 hr after injection
showed markedly decreased transport, indicating that
the decrease was not due to a delay in transport (data
not shown). In contrast, NGF transport was much more
robust in Ts1Cje mice—about 6-fold that seen in the
Ts65Dn mice and about 70% of that seen in 2N controls
(Figure 1A).
Consistent with decreased retrograde transport of en-
dogenous NGF, NGF protein levels were significantly in-
creased in the hippocampus of Ts65Dn mice (Cooper
et al., 2001) without an increase in NGF mRNA in hippo-
campus (Ts65Dn/2N = 0.826 0.27, n = 5, p = 0.51). In ad-
dition, there was a moderate decrease in NGF in the sep-
tum, which due to technical limitations did not reach
statistical significance. In accord with the improvement
in NGF transport in Ts1Cje mice, the amount of NGF was
not different from 2N mice in either hippocampus ([ng/g
tissue (mean 6 SEM)]; 2N = 3.25 6 0.19, n = 4; Ts1Cje =
3.856 0.25, n = 4; p > 0.5) or septum ([2N = 1.956 0.25,
n = 4; Ts1Cje = 2.46 6 0.36, n = 4]; p > 0.5). Thus, NGF
transport was little affected in Ts1Cje mouse.
If, as postulated, failed NGF transport was responsi-
ble for the degeneration of BFCNs in Ts65Dn mice, we
reasoned that the improvement in NGF transport in
Ts1Cje mice would be attended by improvement in the
status of BFCNs. Examining elderly mice, in which
changes in BFCNs in Ts65Dn mice are most evident, in
Ts1Cje mice we found no significant difference with re-
spect to 2N mice in the number or mean cell size of
p75NTR-Ir BFCNs. In contrast, the changes in Ts65Dn
mice could be reconfirmed (Figures 1B and 1C). Extend-
ing these findings by examining another marker for
BFCNs, we used an antibody to TrkA, which selectively
marks BFCNs in the MSN (Yeo et al., 1997). There was
a significant reduction in the number and size of TrkA-Ir
neurons in Ts65Dn as compared with 2N mice. By con-
trast, in Ts1Cje mice there was no significant difference
in number; while a change in size was registered, the de-
viation from 2N mice was significantly less than forTs65Dn mice (Figures 2A and 2B). These data provide
additional support for the assertion that disrupted NGF
transport is linked to BFCN degeneration in models
of DS.
Examining BFCN Axons in Mouse Models of DS
In an earlier study, we detected changes in BFCN axons
in Ts65Dn mice, the most interesting of which was a sig-
nificant change in the distribution of p75NTR immunos-
taining within the dentate gyrus (DG) (Cooper et al.,
2001). To investigate if Ts1Cje mice also escaped this
phenotype, we reevaluated in all three genotypes the
distribution of BFCN axons by examining the optical
density (OD) of p75NTR immunostaining. First, we de-
tected no significant differences in the average OD for
either hippocampus or DG (see Table S1A in the Supple-
mental Data); nor were there changes in the thickness of
the dentate granule cell (DGC) layer or molecular layer
(ML). We then mapped the pattern of p75NTR immunos-
taining in the inferior blade of the DG, from the DGC layer
to the outer ML in mice of all three genotypes. In accord
with an earlier report (Cooper et al., 2001), there was
a change in Ts65Dn mice (Figure 1D and Figure S1 in
the Supplemental Data), with an increase in intensity in
the inner aspect of the ML and a decrease in more
superficial aspects. Given that the overall level of
p75NTR-Ir was unchanged in DG, the findings suggest
that cholinergic terminals are distributed differently
within the ML in aged Ts65Dn mice. In contrast to the
findings in Ts65Dn mice, the pattern of immunostaining
in the DG of Ts1Cje mice was virtually identical to that of
2N mice. Thus, as for the cell bodies of BFCNs, the
abnormal axonal phenotype detected in Ts65Dn was
absent in Ts1Cje mice.
Increased Gene Dose and Expression for App Plays
a Conspicuous Role in Failed NGF Transport
and BFCN Degeneration in Mouse Models of DS
Because Ts65Dn and Ts1Cje mice differed with respect
to NGF transport and the status of BFCNs, this sug-
gested that increased dose of a gene(s) present in
Ts65Dn, but not in Ts1Cje, was responsible. One candi-
date is the amyloid precursor protein (App) gene, the
mouse ortholog of human APP, which is present in three
copies in Ts65Dn but in only two copies in Ts1Cje
(Gardiner et al., 2003). Mouse App is highly orthologous
to human APP at the nucleotide and protein levels
(Yamada et al., 1989) and both the mouse and human
genes are widely expressed in the brain (Golde et al.,
1990). In addition, recent studies have implicated APP
in axon structure and function (Stokin et al., 2005). To
test whether increased App dose disrupts NGF trans-
port, we bred Ts65Dn females with male mice hemi-
zygous for App to produce litters containing: 2N mice
with two copies of App (2N:App+/+); 2N mice with one
copy ofApp (2N:App+/2); Ts65Dn mice with three copies
of App (Ts65Dn:App+/+/+); and Ts65Dn mice with two
copies of App (Ts65Dn:App+/+/2). When examining NGF
transport, as expected, Ts65Dn:App+/+/+ mice showed
a severe defect, achieving onlyw4% of the levels seen
in 2N mice (Figure 1E). Remarkably, Ts65Dn:App+/+/2
mice achieved levels nearly 56% of those in 2N mice.
Thus, deleting one copy of App markedly increased
NGF transport, restoring it to a level similar to that in
Failed NGF Transport in a Down’s Syndrome Model
31Figure 1. NGF Transport and App in Trisomic
Mice
(A) Ts65Dn mice exhibited a marked de-
crease in NGF transport (12.6% 6 2.7% of
2N controls, n = 5, *p < 0.0001). Note that
NGF transport was also markedly decreased
in Ts65Dn mice at age 3 months (not shown).
NGF transport was much greater in Ts1Cje
mice (71.0% 6 5.1% of 2N controls, n = 5,
**p = 0.0016) relative to Ts65Dn mice (p <
0.0001).
(B) The number of p75NTR-Ir BFCNs in Ts65Dn
mice (1601 6 158, n = 5) was significantly
lower than in 2N mice (2150 6 119, n = 10,
*p = 0.021). In contrast, there was no signifi-
cant difference in BFCN number between
Ts1Cje (2096 6 183, n = 6, p > 0.7) and 2N
controls.
(C) The frequency distribution of BFCN cell
profile areas in 2N, Ts65Dn, and Ts1Cje
mice. Note that the curve for Ts1Cje mice ap-
proximates that for 2N mice. In contrast, the
cell profile areas of BFCNs in Ts65Dn mice
(88.37 6 0.65 mm2, n = 5) were significantly
smaller than in 2N mice (103.41 6 4, n = 10,
p = 0.007). There was no significant difference
in the cell profile areas for Ts1Cje (98.3 6 8,
n = 6) and 2N mice (p > 0.6).
(D) The pattern of p75NTR immunostaining in
the inferior blade of the DG. The normalized
OD value is plotted for a line that begins
from the DGC layer and extends to the outer
one-third of the ML. The patterns for
Ts65Dn and 2N differed significantly (signifi-
cant differences marked by [*]). There was
no significant difference between Ts1Cje
and 2N mice.
(E) As expected, NGF transport was markedly
reduced in Ts65Dn:App+/+/+ mice as com-
pared to controls (4.3% 6 2.3%, n = 3, **;
p < 0.0001). However, transport increased in
Ts65Dn:App+/+/2 mice to 56.2% 6 4.5% (n =
3) of that in 2N mice, a highly significant
change (*p = 0.0005).
(F) The BFCN atrophy in Ts65Dn:App+/+/+
mice was not present in Ts65Dn:App+/+/2
mice. Comparing the frequency distribution
of BFCN cell profile areas, there was a sig-
nificant difference (p = 0.045) between
Ts65Dn:App+/+/+ and Ts65Dn:App+/+/2. There
was also a significant difference in the abso-
lute values for cell profile areas between
Ts65Dn:App+/+/+ (103.37 6 5 mm2, n = 6) and 2N mice (116.9 6 5 mm2, n = 5, p = 0.044), but not between 2N mice and Ts65Dn:App+/+/2 mice
(128.28 6 0.9 mm2, n = 2, p = 0.245).
(G) In Ts65Dn mice, but not in Ts1Cje mice, App mRNA levels were increased in the MSN (2N = 100.0% 6 10.8%, n = 5; Ts65Dn = 179.33% 6
22.3%, n = 5; Ts1Cje = 108.19% 6 16.2%, n = 5; 2N versus Ts65Dn, *p = 0.028; 2N versus Ts1Cje, p = 0.916) and hippocampus (2N = 100.0% 6
13.1%, n = 5; Ts65Dn = 152.89 6 13.6, n = 4; Ts1Cje = 118.85% 6 6.5%, n = 5; 2N versus Ts65Dn, **p = 0.027; 2N versus Ts1Cje, p = 0.174).
(H) Increased levels of App mRNA were reflected in increased levels of App protein. The levels of FL-App in the hippocampus of Ts1Cje mice did
not differ significantly from that of 2N mice (2N = 100.0% 6 8%, n = 4; Ts1Cje = 70.7 6 8, n = 4; p = 0.155). However, there was a significant
increase in the levels of FL-App in Ts65Dn mice (2N = 100.0% 6 4.5%, n = 4; Ts65Dn = 143.8 6 4.1%, n = 4; 2N versus Ts65Dn, *p = 0.0004).
Error bars = SEM.Ts1Cje mice. That the defect in NGF transport was not
fully prevented in the Ts1Cje or the Ts65Dn:App+/+/2
mice is evidence that other genes in the trisomic seg-
ment must contribute. We next determined whether de-
leting the extra copy of App influenced the size of
BFCNs. As shown (Figure 1F), while the area of BFCN
cell bodies in Ts65Dn:App+/+/+ was markedly reduced,
in Ts65Dn:App+/+/2 mice it was indistinguishable from
2N mice. These findings provide compelling evidence
that increased gene dose for App contributes signifi-cantly to the disruption in NGF transport and atrophy
of BFCNs in Ts65Dn mice.
Increased gene expression was the most likely expla-
nation for the demonstrated effects of App gene dose.
We first confirmed that App mRNA and full-length App
(FL-App) protein levels are increased in Ts65Dn but
not Ts1Cje mice (Figures 1G and 1H). In addition, as pre-
dicted by genotype, Ts65Dn:App+/+/+ mice exhibited
significantly increased levels of FL-App relative to the
2N controls (Table S2). We conclude that increased
Neuron
32Figure 2. TrkA Expression in BFCNs of Triso-
mic Mice
Stereological estimation of the total number
(A) and cell profile area (B) of TrkA-Ir neurons
in the MSN of Ts65Dn, Ts1Cje, and their 2N
controls. There was a significant reduction
in the number of TrkA-Ir neurons in Ts65Dn
mice compared with 2N mice (2N =
1015.21 6 76.73, n = 11, Ts65Dn = 677.67 6
85.64, n = 5, *p = 0.015). However, no signifi-
cant reduction was found in the total number
of TrkA-Ir cells in the MSN of Ts1Cje mice
(Ts1Cje = 844.42 6 89.37, n = 6, p = 0.298).
The cell profile area of TrkA-Ir cells was as fol-
lows: 2N (119.39 6 7.25 mm2), Ts1Cje
(102.74 6 1.7 mm2), and Ts65Dn (86.67 6 2.69 mm2) mice; (2N versus Ts65Dn, p = 0.0072; 2N versus Ts1Cje, p = 0.02; and Ts1Cje versus
Ts65Dn, p = 0.01). The frequency distribution indicates that while the distribution of profile area was shifted to lower values in Ts65Dn mice,
this was not the case for Ts1Cje mice.
Error bars = SEM.App gene dose was reflected in increased levels of both
the mRNA and protein.
Decreased NGF Transport in Mice Transgenic
for Wild-Type or Mutant Human APP
To examine further a role for increased APP expression
on NGF retrograde transport and BFCNs, we examined
the following: (1) mice Tg for wild-type (wt) human
APP; (2) mice Tg for a mutant of human APP, APPSwe,
known to cause Swedish familial AD (FAD); (3) mice Tg
for a mutant presenilin 1 (PS1A246E) that causes FAD;
and (4) mice Tg for both APPSwe and PS1A246E. In mice
Tg for a yeast artificial chromosome (YAC) containing
the human wt APP gene (Lamb et al., 1993), the pattern
of expression of the transgene is similar to that of mouse
App, and the total (i.e., Tg plus endogenous) mRNA and
protein levels approximate those found in DS and in the
Ts65Dn mouse (Lamb et al., 1993). Western blot studies
on brain of wt APP mice showed anw70% increase, as
compared to non-Tg controls, in total APP and in APP C-
terminal fragments (App-CTF). The same increase was
registered for the release of the Ab peptide from cultured
cortical neurons (Lamb et al., 1997). We found that NGF
transport was modestly but significantly decreased in
Tg mice compared to their non-Tg littermates (Fig-
ure 3A). Thus, increased expression of APP alone exerts
a conspicuous effect on NGF retrograde transport.
To confirm a role for increased APP expression, we
examined a mouse model of AD in which there is in-
creased expression of an APP transgene bearing a mu-
tation that causes FAD. In APPSwe mice the App gene
has been modified to encode the human sequence for
the Ab domain together with the mutations linked to
Swedish FAD (K595N, M596L) (Borchelt et al., 1997).
Full-length APP is increased about 2-fold over the level
of endogenous mouse App and APP-CTFs are in-
creased by at least this amount (Borchelt et al., 1996;
Jankowsky et al., 2004). NGF transport was significantly
decreased, achieving only 62% of that seen in non-Tg
controls (Figure 3B). Decreased NGF transport could
be due to a decrease in the number of BFCNs, de-
creased NGF binding to its receptors on the axons of
these neurons, or decreased internalization of receptor-
bound NGF. Because in comparing APPSwe Tg mice and
non-Tg controls we detected no significant differences
in any of these parameters (Figures 3C–3F), the findingspoint to an intracellular locus for the NGF transport
defect in APPSwe BFCNs axons, as was seen in Ts65Dn
mice (Delcroix et al., 2004).
Mutations in PS1 modify APP processing (Price and
Sisodia, 1998). In mice Tg for both APPSwe and mutant
human PS1A246E, the increase in FL-APP is equivalent
to that in APPSwe mice—i.e., increasedw2-fold (Borch-
elt et al., 1997). We found that NGF transport was more
compromised in the doubly Tg mice than in those har-
boring only the APPSwe transgene; transport was re-
duced to w40% of control levels (Figure 3B; p < 0.05).
As in APPSwe mice, the transport defect in doubly Tg
mice was not accompanied by significant decreases in
the size or number of BFCNs, in NGF receptor binding,
or in NGF internalization (Figures 3E and 3F). The failure
to register a change in BFCN size or number in these
mice differentiates them from Ts65Dn mice and raises
the possibility that only with more severe changes in
NGF transport do BFCNs become atrophic and lose
immunoreactivity for p75NTR.
Studies to Elucidate the Mechanism by which
Increased App Expression Disrupts NGF Transport
To begin to elucidate the cellular mechanism by which
App overexpression compromises transport, we asked
which product(s) ofApp gene expression is responsible.
Evidence against a role for Ab in the Ts65Dn mouse is
that there is no increase in the level of either Ab40 or
Ab42 in the whole brain or the hippocampus (Table
S3). These findings directed our attention to FL-App
and its other processed products. We noted with inter-
est recent findings suggesting that increased levels of
FL-App and/or one or more of its transmembrane, C-ter-
minal-containing products could play a role in modifying
axonal structure and function (Gunawardena and Gold-
stein, 2001). Indeed, these findings point to both axonal
pathology in cholinergic neurons that overexpress APP
and an effect on severity of gene dose for a motor pro-
tein, kinesin 1 (Stokin et al., 2005). We examined FL-App
and transmembrane C-terminally intact App products,
comparing the levels in Ts65Dn, Ts1Cje, and 2N mice.
In Ts65Dn, but not in Ts1Cje, the levels of both the
FL-App and App-CTFs—i.e., C-83 plus C-99—were in-
creased in hippocampus roughly in proportion to gene
dose (Figures 4C and 4D). When examined with respect
to NGF transport, increased FL-App was associated
Failed NGF Transport in a Down’s Syndrome Model
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nalization in APP Tg Mice
(A) Mice that expressed wt human APP at
levels comparable to Down’s syndrome
showed a modest but significant reduction
in NGF transport to 74.2% 6 7.4% (n = 4,
*p = 0.002) of that of non-Tg controls.
(B) In comparison with non-Tg mice, elderly
mice (age 19–20 months) overexpressing
APPSwe or both APPSwe and PS1A246E
showed significantly lower values for NGF
transport (62.0% 6 5.7%, n = 5, *p = 0.029;
and 41.35% 6 1.12%, n = 3, ***p = 0.005, re-
spectively). The amount of NGF transported
in PS1A246E mice was significantly greater
than that in APPSwe/PS1A246E mice (**p =
0.01).
(C) There was no difference in the number of
p75NTR-Ir neurons between non-Tg mice
and the singly or doubly Tg mice. BFCN num-
ber: Non-Tg (1715 6 79, n = 5), APPSwe/
PS1A246E (15676 176, n = 6), APPSwe (17316
118, n = 6), PS1A246E (1391 6 158, n = 5).
(D) Nor was there a difference in cell profile
areas with respect to non-Tg mice. Cell pro-
file area: Non-Tg (84.66 6 2.3 mm2), APPSwe/
PS1A246E (90.57 6 2.8 mm
2), APPSwe (94.86 6
5.0 mm2), and PS1A246E (86.02 6 1.4 mm
2).
(E) There was no significant difference in the
amount of NGF binding between the non-Tg
controls and any of the Tg mice (Kruskal-
Wallis test: p = 0.1603), although there was
a definite trend toward increased binding to
synaptosomes from PS1A246E. The data re-
port the results of the following number of
determinations (non-Tg = 6, APPSwe = 6,
APPSwe/PS1A246E = 8, PS1A246E = 8).
(F) A significant difference in NGF internaliza-
tion was found between the four groups (p =
0.0116). This was due to a significant increase
in NGF internalization in PS1A246E mice (Non-
Tg versus PS1A246E, *p = 0.014). This increase
was correlated with increased NGF transport
compared to non-Tg controls (141.58% 6
10.9%, n = 5, p = 0.040,) (see [B]).
Error bars = SEM.with decreased NGF transport, but no significant linear
correlation was evident across genotypes (r =
20.7582, p = 0.452) (Figure 4C). NGF transport was cor-
related with the concentration of App-CTFs (r = 20.999,
p = 0.007). Increased levels of FL-App and CTFs were
uniformly detected in trisomic mice (Table S2). To inves-
tigate if the increases in FL-App and App-CTFs in
Ts65Dn mice were present in axonal terminals, we car-
ried out studies on hippocampal synaptosomes and
found increased levels for both FL-App and App-CTFs
(Figures 4A and 4B). These data raise the possibility
that increases in FL-App and other transmembrane
Apps, including App-CTFs, negatively influence NGF
transport.
One lead for elucidating the mechanism of disrupted
NGF transport comes from recent studies suggesting
that App overexpression causes the enlargement of
early endosomes (EEs) in Ts65Dn BFCNs. Increased
EE size is a pathological signature also seen in DS andAD (Cataldo et al., 2003). The finding can be envisioned
as having a role in compromising NGF transport: endo-
cytosis of NGF carries it to EE, retrograde transport of
NGF occurs within EEs (Delcroix et al., 2003), and en-
larged EEs may be transported ineffectively (Carter
and Sorkin, 1998; Seet and Hong, 2001). To ask if in-
creased App expression was registered within EEs, we
used confocal immunostaining. Vesicular acetylcholine
transporter (VAChT) immunoreactivity was used to
mark BFCN axons in hippocampus and Rab5b immu-
nostaining marked EEs (Figures 5 and 6). We saw that
(1) cholinergic terminals are enlarged in Ts65Dn mice
(Figure 6Ba); (2) cholinergic terminals of both 2N and
Ts65Dn mice contain EEs (Figures 5Aa–5Ad); (3) cholin-
ergic terminals also contain App, detected using anti-
bodies to either the App N terminus (Figures 5Ae–5Ah
and Figures 6Aa–6Ah), the C terminus (Figures 5Ai–
5Al), or the App-CTF produced by b-secretase cleavage
(Figures 5Am–5Ap); (4) immunostaining for App and for
Neuron
34Figure 4. App Metabolism, Function, and Lo-
calization in Ts65Dn Mice
(A and B) Western blot depicting the levels of
FL-App and App-CTF in synaptosomes pre-
pared from the hippocampus of 2N and
Ts65Dn mice (Arbitrary Units; FL-App: 2N =
8868.5 6 26.16, Ts65Dn = 15873.5 6 41.72;
App-CTF: 2N = 7632.5 6 1195.71, Ts65Dn =
10162.5 6 989.24; n = 2, with each experi-
mental group using the tissues of three mice).
(C and D) Correlation between the levels of
FL-App or its CTFs (C-83 plus C-99) in hippo-
campus and NGF transport. FL-App (percent
2N): 2N = 100.0 6 4.5, n = 4; Ts1Cje, 70.70 6
8, n = 3; Ts65Dn = 143.8 6 4.1, n = 4; 2N ver-
sus Ts1Cje, p = 0.149, 2N versus Ts65Dn, p =
0.020); App-CTFs: 2N = 100.0 6 3.3, n = 4;
Ts1Cje = 109.89 6 16.71, n = 3; Ts65Dn =
131.43 6 11, n = 4; 2N versus Ts1Cje, p =
0.723, 2N versus Ts65Dn, p = 0.021). There
was no significant linear correlation between
FL-App and NGF transport (r = 20.7582, p =
0.452), but a significant negative correlation
was detected between the amount of App-
CTFs and NGF transport (r = 20.999, p =
0.007).
(E and F) Immunoprecipitation of radiola-
beled NGF following hippocampal injections
in vivo. (E) 18 hr following injection of radiola-
beled NGF, the hippocampus (Hp), fimbria-
fornix (Fb) and septum (Sept) were dissected
and homogenized, and lysates were immuno-
precipitated first with antibodies to TrkA and
then to p75NTR. NGF bound to its receptors
was detected in immunoprecipitates after
SDS-PAGE and blotting by exposing mem-
branes to phosphoimaging. Though, as ex-
pected from direct assay of radioactivity,
much less NGF was detected in immunopre-
cipitates of fimbria-fornix and septum, we
routinely detected a signal that was above
background in 2N mice, indicating that NGF
was internalized and transported on its re-
ceptors. Specific binding and internalization
is evident in the absence of a signal above background in experiments in which a 200-fold excess of NGF was injected together with radiolabeled
NGF. (F) NGF was bound to TrkA and to p75NTR in the hippocampus of both 2N and Ts65Dn mice. Because immunoprecipitations did not quan-
titatively bring down NGF, no attempt was made to compare the amount of NGF recovered from different tissues or between 2N and Ts65Dn
mice.
(G) Immunoisolation of EEs from PC12 cells showed that TrkA is present in the same endosomes as App and that App is present together with
p75NTR in EEs that contain Rab5b.
(H) Western blotting for the DIC, p150Glued, and p50 dynamitin showed no alterations in levels in hippocampal synaptosomes from Ts65Dn mice.
Error bars = SEM.App-CTF is increased in cholinergic terminals of Ts65Dn
mice (Figures 6Aa–6Ah and 6Bb and 6Bc) ; and (5) App
and App-CTF are present in EEs in cholinergic terminals
in both Ts65Dn and 2N mice (Figures 5Am–5At, Fig-
ure 6Bd, Table S5). Given extensive colocalization of
App and App-CTF with Rab5b in VAChT-positive termi-
nals in both Ts65Dn and 2N mice (w100% for App; for
App-CTF, see Table S5), we conclude that the increase
in App and App-CTF in cholinergic axons includes EEs.
To determine whether or not NGF was also present in
EEs in BFCN axons, we incubated hippocampal slices
with biotinylated NGF (Bt-NGF) and stained with strep-
tavidin Quantum dots. NGF was robustly detected in
structures whose shape corresponded to axons; the
vast majority of NGF (w91%) was present in cholinergic
axons, as indicated by colocalization with VAChT (not
shown). Staining for NGF was extensively colocalized
with that for Rab5b in both Ts65Dn and 2N mice (Figures5Ba–5Bd). The presence of NGF within EEs was due to
specific binding and internalization because staining
was eliminated when sections were incubated with Bt-
NGF in the presence of a 500-fold excess of unlabeled
NGF (not shown). Next we gathered evidence that TrkA
and p75NTR, the receptors for NGF which are present
in BFCNs and their axons (Jaffar et al., 2001; Yeo et al.,
1997), mediated NGF binding and internalization. After
injecting radiolabeled NGF into the hippocampus in vivo,
we could immunoprecipitate NGF bound specifically to
both TrkA and p75NTR in the hippocampus; as expected,
smaller amounts were immunoprecipitated from the fim-
bria-fornix and septum (Figure 4E). Moreover, NGF was
readily detected in immunoprecipitations for both re-
ceptors in the hippocampus of both 2N and Ts65Dn
mice (Figure 4F). p75NTR was present within cholinergic
axons (Figures 5Be–5Bh). Because of limited availability
of antibodies, we were not able to show directly that
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ceptors in EEs in Cholinergic Terminals
(A) Confocal microscopy studies in the CA2
area of 2N hippocampus examining colocali-
zation of markers for cholinergic axons
(VAChT), EEs (Rab5b), App, CTF-App and
p75NTR. Colocalization was detected for
Rab5b and VAChT (Aa–Ad) and VAChT and
App in EEs (Rab5b), using antibodies di-
rected against the N terminus (Ae–Ah), C ter-
minus (Ai–Al), or App-CTF (Am–Ap). EEs also
were found to contain App in cholinergic
terminals (Aq–At). Scale bar, 10 mm (Aa–Ap),
5 mm (Aq–At).
(B) Bt-NGF, specifically bound and internal-
ized in hippocampal slices, was extensively
colocalized in Rab5b-Ir structures (Ba–Bd).
p75NTR-Ir was present in cholinergic axon ter-
minals (Be–Bh). Scale bar, 10 mm (Ba–Bh).
The same patterns for colocalization were
evident in the Ts65Dn hippocampus (not
shown). Dotted areas are enlarged in the
adjacent panels to the right. Arrows show co-
localization. The OD of Rab5b positive puncta
within BFCN terminals was less in Ts65Dn
mice (2N = 144 6 1.4 OD, Ts65Dn = 135 6
1.72 OD, p = 0.001).p75NTR and TrkA were present in EEs in BFCN axons.
However, there is strong evidence that both receptors
are present in EEs in other NGF-responsive cells (Del-
croix et al., 2003). Finally, we could demonstrate that
NGF and its receptors are present together with App in
EEs. In a fraction enriched in EEs from PC12 cells, we
showed in immunoadsorption studies that membranes
adsorbed with antibodies for either Rab5b or for pTrkA
also contained App and p75NTR (Figure 4G). We con-
clude that increased App expression is registered in
EEs of BFCN axons and that these endosomes also con-
tain NGF that is specifically bound and internalized via
its receptors.
NGF-Containing EEs Are Abnormal in Ts65Dn Mice
To explore further the status of EEs in cholinergic termi-
nals, we examined their size and immunostaining prop-erties in the hippocampus of Ts65Dn and 2N mice. There
was no change in the average size of EEs in Ts65Dn
(2N = 0.34 6 0.02 mm2; Ts65Dn = 0.31 6 0.03 mm2, p =
0.32), but we did note a small but significant change in
the intensity of Rab5b immunostaining in the Ts65Dn
hippocampus (OD: 2N = 144 6 1.4; Ts65Dn = 135 6
1.72, p = 0.001). To examine specifically the EEs that
contain App, we carried out triple-labeling studies. The
findings were as follows: (1) both App and App-CTF
were extensively localized in EEs in cholinergic termi-
nals (Table S5), and (2) there was significant enlarge-
ment of these EEs (for App N terminus see Figure 6Bd;
App-CTF: 2N = 0.260 6 0.016 mm2, n = 3; Ts65Dn =
0.407 6 0.03, n = 3, p = 0.002). To examine the EEs that
contain NGF, hippocampal slices were incubated with
Bt-NGF and then processed for immunostaining for
Bt-NGF and Rab5b. In the Ts65Dn hippocampus, we
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in Ts65Dn and 2N Mice
(A) Photomicrographs depicting App N termi-
nus in VAChT-positive terminals in the CA2
area of the hippocampus of 2N (Aa–Ad) and
Ts65Dn (Ae–Ah) mice. App-positive choliner-
gic terminals were found to be enlarged in
Ts65Dn mice. Dotted areas are enlarged in
the adjacent panels to the right. Arrows
show colocalization. Scale bar, 10 mm (Aa–
Ah).
(B) Quantitative analysis indicated that the
size of VAChT-positive terminals was signifi-
cantly increased in Ts65Dn mice (2N = 0.80
6 0.02 mm2, Ts65Dn = 0.93 6 0.04 mm2, p =
0.003 [Ba]). In addition, the amount of App im-
munostaining of both N terminus (Bb) and C
terminus (Bc) in VAChT-positive terminals
was significantly increased in Ts65Dn mice
(N terminus: 2N = 0.69 6 0.03 mm2, Ts65Dn =
0.83 6 0.04 mm2, p = 0.005; C terminus: 2N =
0.40 6 0.02 mm2, Ts65Dn = 0.49 6 0.03 mm2,
p = 0.02). The size of App N terminus-posi-
tive-EEs (Bd) in cholinergic terminals was sig-
nificantly larger in Ts65Dn compared with 2N
mice (2N = 100% 6 7.2%, n = 6; Ts65Dn =
144.67% 6 7.9%, n = 5; p = 0.0001).
Error bars = SEM.detected a significant increase in the area of colocaliza-
tion for NGF and Rab5b, pointing to an increase in the
size of EEs that contain NGF. Indeed, the average size
was increased to w180% of that in 2N mice (2N =
0.696 0.06 mm2, n = 4; Ts65Dn = 1.246 0.12 mm2, n = 3;
p < 0.001). Taken together, the data are evidence for
the presence in cholinergic terminals of Ts65Dn mice of
enlarged EEs that contain NGF, App, and App-CTF.
Whether or not the defect in NGF transport is linked
to a change in endosomal size or function, and the rela-
tionship (if any) to overexpression of App, is yet to be
established.
Evidence for Selective Disruption of Retrograde
Transport in Ts65Dn Mice
In view of prior studies showing that both TrkA and
p75NTR are engaged in retrograde transport of NGF
(Kiss et al., 1993), the marked decrease in transport de-
tected herein suggests that both receptors are affected.
Remarkably, however, the defect in transport is not gen-
eral because we detected no decrease in the retrograde
transport of Fluoro-Gold (FG); (percent area covered by
FG fluorescence [mean 6 SEM] [n = 7]: 2N = 8.85% 6
1.9%; Ts65Dn = 8.85% 6 1.24%; p = 0.949; Figures 7A
and 7B), a molecule widely used to examine retrograde
transport (Wessendorf, 1991). Because cholinergic neu-
rons represent the principle source of afferents to the
hippocampus from MSN, the data are evidence against a
universal, marked defect in retrograde transport in theseneurons. In concert with this finding, we also failed to
detect changes in components of the dynein-dynactin
complex in the Ts65Dn hippocampus (Figure 4H).
Thus, disrupted retrograde transport may affect a subset
of endosomal cargoes.
Discussion
Our studies establish a link between disrupted retro-
grade transport of NGF, a target-derived neurotrophic
factor for BFCNs, and the degeneration of these neurons
in Ts65Dn mice, which are segmentally trisomic for
mouse chromosome 16 and serve as a model for DS.
We used a genetic approach to show that increased
gene dose for App contributes to the creation of both
phenotypes. Deleting a copy of App in trisomic mice
led to a marked improvement in NGF transport and
BFCN morphology. NGF transport was compromised
significantly, but to a lesser extent, by transgenesis for
either wt or mutant APP, thus confirming that increased
expression of this gene is linked to the transport defect.
However, in these mice there was no evident degenera-
tion of BFCNs. Taken together, the findings are evidence
that in the context of trisomy for mouse genes homolo-
gous to those on human chromosome 21, increased
gene dose and overexpression of App compromises
NGF transport and promotes degeneration of BFCNs.
The retrograde transport of target-derived neurotro-
phic factor signals plays an important role in the survival,
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37differentiation, and maintenance of many neurons. An
increasing body of evidence supports the view that ret-
rograde transport of signaling endosomes, in which the
neurotrophic factor remains bound to its receptor, is an
important means by which trophic signals are moved
(Howe and Mobley, 2004; Zweifel et al., 2005). The close
correlations between the NGF transport and BFCN de-
generative phenotypes demonstrated herein in models
of DS are evidence to support the view that disrupted
NGF transport is responsible for BFCN degeneration.
A causal role is supported by studies showing a correla-
tion between NGF levels in targets of innervation of ma-
ture neurons and the status of key parameters, including
the expression of neurotransmitter genes and the size of
cell bodies (Sofroniew et al., 1993). Indeed, experiments
in which NGF levels are reduced through gene disrup-
tion or production of neutralizing antibodies create phe-
notypes quite similar to those seen in the Ts65Dn mouse
(Capsoni et al., 2000; Chen et al., 1997). Moreover, de-
creased NGF transport to the cell bodies of BFCNs in
the aged rat was correlated with atrophy (Cooper
et al., 1994). Finally, as noted above, when delivered
by a method that obviated the need for retrograde trans-
port, NGF treatment rescued BFCN phenotypes in
Ts65Dn mice. The current findings thus provide compel-
ling support for the view that failed NGF transport is re-
sponsible for BFCN degeneration in the Ts65Dn mouse.
Nevertheless, to demonstrate that NGF transport failure
in Ts65Dn mice causes degeneration of BFCNs will re-
quire studies in which specifically disrupting NGF sig-
naling is shown to prevent the rescue of the degenera-
tive phenotype achieved by reducing App gene dose
in these mice.
One may question whether failed NGF retrograde
transport is specific to this neurotrophin (NT). BDNF
and NT3 are also transported in BFCNs and conceivably
could be affected. In an attempt to address this point, in
an earlier study (Cooper et al., 2001) we examined trans-
port of the NTs BDNF and NT3 using the same methods
as for the current study; we found that transport was be-
low the limits of detection. Thus, it would appear that
transport of these NTs is less robust than for NGF. To
address the issue of specificity in the current study,
we carried out studies using FG, a marker often used
Figure 7. Retrograde Transport of Fluoro-Gold in Ts65Dn Mice
(A) Fluoro-Gold transport to the MSN in 2N and Ts65Dn mice, visu-
alized with UV illumination.
(B) There was no significant difference between the total area cov-
ered by FG between 2N and Ts65Dn mice (2N = 8.85 6 1.9, n = 7;
Ts65Dn = 8.85 6 1.25, n = 7). Note that there also was no difference
between genotypes in the area identified as MSN.
Error bars = SEM.to examine retrograde transport. Our FG injection study
showed no differences between Ts65Dn and 2N mice,
pointing to no generalized failure in retrograde transport
in these mice. The result encourages the view that many
cargoes may be moved normally, but does not rule out
defect in the transport of other NT cargoes. Indeed, we
expect that such defects may exist. Transport studies
examining a variety of cargoes will be needed to fully
define the defect.
It is of interest to consider the time course for the de-
fects in NGF transport in relation to changes in BFCNs.
Based on our current findings and those provided previ-
ously (Cooper et al., 2001), decreased NGF transport
precedes neuropathological changes in BFCN cell bod-
ies in Ts65Dn mice by at least 9 months. Indeed, the de-
fect was present at the earliest age examined, 3 months
(not shown). At 3 months, there is also evidence of ab-
normal EEs, as documented herein. Moreover, there
are changes in the distribution of BFCN axons as early
as 6 months. Thus changes in both axonal structure
and function predate changes in the size and number
of cell bodies of BFCNs. Whether or not axonal changes
predate more subtle pathological alterations in BFCN
somas will require additional ultrastructural studies.
Given the correlations demonstrated between App
gene dose and protein levels in the DS models, our re-
sults are evidence that, in the context of the other genes
present in Ts65Dn mice, increased levels of App and/or
its products contribute conspicuously to marked de-
creases in NGF transport and to the pathogenesis of de-
generation. It is an open question as to whether or not
increased expression of App alone is sufficient to cause
BFCN dysfunction. Though we detected significant de-
creases in NGF transport, Tg human APP was not asso-
ciated with obvious degenerative changes. It is perhaps
noteworthy that the defect in NGF transport in APP Tg
mice (40% to 60% of non-Tg) was approximately the
same as in Ts65Dn mice deleted for one copy of App
(w50%) and far less severe than in Ts65Dn mice
(w10%). Moreover, while we detected no change in
the distribution of BFCN axons within hippocampus of
APPSwe mice, a recent study did demonstrate the pres-
ence of large varicosities in these axons well before the
deposition of plaques (Stokin et al., 2005), showing that
more subtle degenerative phenotypes are present. Con-
ceivably, such changes could be linked to impaired NGF
transport.
In pointing to the importance of gene dose and over-
expression of a specific gene in the setting of trisomy,
the current study is expected to enhance progress in un-
derstanding the cellular mechanism of pathogenesis for
neurodegeneration in DS. It makes the argument that
even in the context of a complex genetic lesion, in-
creased dose for but one gene can impact important
features of neuronal structure and function. Though
other genes in the trisomic segment must contribute to
the defect in NGF transport and to degenerative
changes, our report draws attention to a surprisingly ro-
bust effect of the dose forApp. It is noteworthy that a pa-
tient with partial trisomy for human chromosome 21 that
did not include the APP gene exhibited no age-related
cognitive decline and no AD-related pathology (Prasher
et al., 1998). It is intriguing then that increased gene dose
forAPPmay contribute significantly to the pathogenesis
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38of AD-related changes and dementia in people with DS,
including the degeneration of BFCNs. If so, treatments
to reduce APP gene expression may prove valuable. In
documenting the importance of gene dose, the current
findings also recall the neurodegenerative phenotypes
created by small changes in the doses of other wild-
type genes in Charcot-Marie-Tooth disease Type 1A
(Lupski et al., 1991), Pelizaeus Merzbacher disease (Ho-
des et al., 2000), Parkinsonism (Singleton et al., 2003),
and Rett syndrome (Van Esch et al., 2005). Indeed, a re-
cent report links an increase in gene dose forAPP in sev-
eral families with early onset AD with cerebral amyloid
angiopathy (Rovelet-Lecrux et al., 2006). While the de-
generative mechanism induced by increased gene
dose and expression will almost certainly be specific
to the disorder in question, it is apparent that for some
genes even apparently small departures from normal
can seriously perturb neuronal function and viability.
Our findings motivate studies to examine what role is
played by App in endosomal transport, and what
changes are induced by increased App gene expression
in the trafficking of neurotrophic signals. The first step is
to elucidate which products of App contribute and
where they act. Given the early appearance of Ab-con-
taining plaques in the brains of individuals with DS (Le-
mere et al., 1996), and the demonstration that the Ab
peptide is responsible for cellular toxicity both in vivo
and in vitro (see Bossy-Wetzel et al., 2004 and Selkoe,
2002) we considered whether or not Ab compromises
NGF transport in the Ts65Dn mouse. Remarkably, we
detected no increase in the levels of Ab peptides in the
Ts65Dn mouse. We conclude, therefore, that this pep-
tide is unlikely to contribute to the NGF transport failure
in these mice. In Ts65Dn mice, a much more convincing
case can be made for increased levels of FL-App and the
App-CTFs. Indeed, the levels of App-CTFs were signifi-
cantly inversely correlated with NGF transport, raising
the possibility that this species may play a role. Unan-
swered is the question as to whether or not increased
levels of Ab would impair NGF transport in other Tg
mice, including those that model the neuropathology
of AD. Human Ab40 and Ab42 are readily measurable
in mice Tg for either APPSwe or for both APPSwe and
PS1A246E (Borchelt et al., 1996; G. Stokin, unpublished
data) and elderly mice of each genotype show evidence
of AD-related pathology (Borchelt et al., 1997). There-
fore, a role for increased Ab peptide in contributing
to the NGF transport defect in these mice cannot be
excluded.
Pointing to an intra-axonal locus for disrupting trans-
port, earlier studies showed that NGF binding and inter-
nalization in hippocampal synaptosomes was not de-
creased (Cooper et al., 2001), findings recapitulated
herein in Tg APP mice. Remarkably, in mice Tg for only
mutant PS1, we detected increases in NGF binding, in-
ternalization, and transport. Given that these measures
were normal in the doubly Tg mice (APPSwe/PS1A246E),
the results were surprising. While a number of possibil-
ities can be offered to explain the findings, we note that
others have shown that expressing mutant PS1 restricts
APP trafficking in axons (Cai et al., 2003). As a specula-
tion, preventing entry of APP into axons may enhance
anterograde trafficking of NGF receptors to axon termi-
nals, a change that would be most evident in the ab-sence of increased APP expression. The increase in ret-
rograde transport would then simply reflect an increase
in binding and internalization of NGF. Alternatively, in
addition to enhancing anterograde transport, mutant
PS1 may to a lesser extent also reduce retrograde trans-
port of NGF. This would result in a mismatch between
binding and internalization on the one hand and trans-
port on the other. Indeed, we noted that the increase
in transport in mutant PS1 mice (w40%) was not as large
as that for internalization (w100%). Under this view, mu-
tant PS1 acting alone would both increase delivery of
NGF receptors to axon terminals and also modestly
compromise NGF retrograde transport. An effect of mu-
tant PS1 on retrograde transport would then further ex-
acerbate the decrease in transport in mice transgenic for
both APPSwe and PS1A246E. While noting that the magni-
tude of the increased deficit in transport between
APPSwe and the doubly transgenic mice might well be
explained in this way, we believe that other interactions
between the products of these transgenes may also
contribute.
Finally, the current study raises the possibility that the
EE constitutes a potential locus for disrupted NGF trans-
port within cholinergic axons in Ts65Dn mice. Immunos-
taining for App and App-CTF is increased in EEs and this
same compartment contains NGF and its receptors.
Moreover, we provide evidence that these EEs contain
NGF and are enlarged in the Ts65Dn hippocampus,
showing that this compartment is abnormal. In view of
earlier studies linking enlargement of EEs and App
gene dose in the Ts65Dn mouse (Cataldo et al., 2003),
and the important role played by EEs in retrograde
transport of NGF and its signals (Delcroix et al., 2004),
it is tempting to speculate that increased App in EEs is
implicated in the NGF transport defect. However, this
association is far from certain. Indeed, Cataldo and co-
workers failed to see the increase in EE size in mice Tg
for APP, while in the current study we show decreased
transport of NGF in such mice. One possibility is that
an endosomal abnormality other than size is linked to
increased presence of App and abnormal transport.
But important alternatives to abnormal endosomes can
be envisioned to play a role, including, for example,
changes in the axonal cytoskeleton and the provision
of ATP for retrograde motors. Future studies will be
needed to define the mechanism and locus for failed
transport and neurodegeneration in Ts65Dn mice.
Our findings build on an emerging story for the impor-
tance of failed axonal transport in neurodegeneration
(Goldstein, 2003; Salehi et al., 2003). In so doing, they
suggest that a focus on this aspect of the biology of




Ts65Dn and Ts1Cje Mice
Age-matched controls were used for all experiments. Unless other-
wise noted, only males were used. The Ts65Dn mouse colony was
maintained by crossing Ts65Dn females (originally obtained from
Jackson Laboratory, Bar Harbor, ME) to C57BL/6JEi 3 C3H/HeSnJ
(B6EiC3Sn) F1 males (Jackson Laboratory). Fibroblasts or lympho-
cytes were karyotyped to identify 2N and Ts65Dn mice. To generate
Ts1Cje mice on a similar genetic background, Ts1Cje mice on the
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39C57BL/6JEi background were crossed with C3H/HeSnJ mice and
the resulting Ts1Cje mice were crossed to B6EiC3Sn F1 mice
(Sago et al., 1998). Ts1Cje mice were genotyped using multiplex
polymerase chain reaction (PCR) primers for neomycin (Neo) and
for a glutamate receptor, ionotropic, Kainite 1 (Grik1, as internal con-
trol) as previously described (Sago et al., 1998). All mouse breeding
was approved by the Committee on Animal Research at the centers
involved (Stanford University, UCSF, UCSD, and Case Western Re-
serve University) and all the studies using mice were approved by
the Stanford University Committee on Animal Research.
Ts65Dn Mice Carrying Only Two Copies of Amyloid Precursor
Protein
In order to generate Ts65Dn:App+/+/2 mice, Ts65Dn female mice
were mated with male mice hemizygous for App, in which App
was inactivated by deleting the App promoter and its first exon
(Zheng et al., 1996). Male hemizygous App mice were kept on
the C57BL/6J background. The product of litters included 2N
mice with two copies of App (2N:App+/+), 2N mice with one copy of
App (2N:App+/2), Ts65Dn mice with the three copies of App
(Ts65Dn:App+/+/+), and Ts65Dn mice with two copies of App
(Ts65Dn:App+/+/2).
Wild-Type APP Transgenic Mice
Mice harboring a YAC of 650 kb containing the gene for human APP
were produced as indicated (Lamb et al., 1993) and carried on the
C57BL/6J background.
APPSwe, Presenilin 1 (PS1)A246E, APPSwe/PS1A246E, and Their
Non-Tg Littermates
These mice were maintained on a mixed (C3H/HeJ and C57BL/6J)
background. The APPSwe mouse expresses a chimeric mouse/
human APP695 containing the human Ab domain and mutations
(K595N, M596L) linked to FAD (Goate et al., 1991). PS1A246E mice
carry a mutant transgene for human PS1 (A246E) (Borchelt et al.,
1997). To generate doubly Tg mice (i.e., APPSwe/PS1A246E mice),
APPSwe mice (C3H/HeJ 3 C57BL/6J) were crossed with PS1A246E
(C3H/HeJ 3 C57BL/6 F3) mice.
Retrograde Transport Studies
NGF
NGF was iodinated and injected stereotactically in hippocampus as
described (Cooper et al., 2001, see also Supplemental Experimental
Procedures). 2N, Ts1Cje, and Ts65Dn used for transport studies
were 6 to 7 months old. APP wt-Tg, non-Tg, Ts65Dn:App+/+/+, and
Ts65Dn:App+/+/2 mice were 10 to 12 months old. APPSwe,
PS1A246E, APPSwe/PS1A246E, and the non-Tg control mice were 19–
20 months old.
Fluoro-Gold
Twelve-month-old 2N and Ts65Dn mice were anesthetized with a
combination of ketamine (60 mg/kg, i.p.) and xylazine (12 mg/kg),
both injected i.p. and placed in a stereotaxic apparatus. Using a
mouse brain atlas (Hof et al., 2000), unilateral injections (0.2 ml
each over 12 min) were made with Fluoro-Gold (Fluorochrome,
Inc, Englewood, CO; 4% in water) at three sites encompassing the
rostrocaudal extent of the hippocampus. After 24 hr, mice were
deeply anesthetized, perfused, and postfixed in 4% paraformalde-
hyde overnight at 4ºC prior to dehydration in 20% sucrose overnight
and vibratome sectioning (200 mm). Sections were mounted and
coverslipped. Retrograde labeling was analyzed under epifluores-
cence illumination with a Nikon microscope coupled to a Spot Cam-
era (Diagnostic Instruments Inc, MI). Images were captured and then
thresholded to yield a distribution for pixels that conformed to the
intensity of staining as determined visually. The area for analysis
was the MSN, as masked to account for the distribution of labeled
cells. The percentage of this area covered by label was then deter-
mined (Image Pro Plus).
Cholinergic Neuron Morphology
BFCN Cell Bodies in the MSN
BFCNs were identified by immunohistochemical staining for p75NTR,
an NT receptor that is localized specifically to cholinergic neurons in
the basal forebrain (Koh and Loy, 1989); in other experiments these
neurons were detected using immunostaining for TrkA (Holtzman
et al., 1995, see also Supplemental Experimental Procedures). Nine-
teen- to twenty-two-month-old 2N, Ts1Cje, and Ts65Dn mice were
used for these morphological studies.BFCN Innervation of Hippocampus
To examine cholinergic axons in the hippocampus, we examined the
overall intensity of immunostaining for p75NTR and ChAT in the hip-
pocampus (see Supplemental Experimental Procedures).
Immunostaining Studies
Colocalization Studies for p75NTR and ChAT in Neurons
of the Medial Septum
2N and Ts65Dn mice were perfused, and sections were stained and
analyzed for colocalization between p75NTR and ChAT as described
in the Supplemental Experimental Procedures. One 2N and one
Ts65Dn (both 3.5 months of age) were used for these studies.
Examining Rab5b, APP, and p75NTR in Cholinergic Axons
in the Hippocampus
Immunostaining studies were used to define the presence of Rab5b,
App, and p75NTR in cholinergic terminals visualized by using an
antibody against VAChT (AB1578, Chemicon; 1:500), the transporter
for acetylcholine (Cobb et al., 1999). Hippocampal sections were
prepared, stained, and analyzed using confocal microscopy as
described in the Supplemental Experimental Procedures. 2N and
Ts65Dn mice (age 3 to 4 months) were used for all these studies.
Defining the Locus of NGF that Is Bound and Internalized
Using Bt-NGF in Hippocampal Slices
We used Bt-NGF to define the locus of NGF that is bound and inter-
nalized in hippocampus. NGF was biotinylated using EZ-link biotin-
PEO-amine (Pierce, Rockford, IL) according to a published protocol
(Bronfman et al., 2003). Bt-NGF was fully active biologically, as ex-
amined by its potency in induction of TrkA phosphorylation (pTyr
490) in PC12 cells. Hippocampal slices were prepared for Bt-NGF
binding and internalization studies as described (Kleschevnikov
et al., 2004, see also Supplemental Experimental Procedures).
Three- to four-month-old Ts65Dn (n = 2) and 2N (n = 2) mice were
used for these studies.
Immunoprecipitation of Radiolabeled NGF following Injection
In Vivo
125I NGF (0.3 ml) was injected in the hippocampus as described
above. At 12 hr after injection, brains were removed and the hippo-
campus, fimbria-fornix, and septum were rapidly dissected and
studied as described in the Supplemental Experimental Procedures.
Three-month-old 2N and Ts65Dn mice were used for these studies.
Immunoisolation of EEs
An EE-enriched fraction was isolated from NGF-treated PC12 cells
using an established method (Wu et al., 2001). The membrane frac-
tion was collected. An aliquot (50 mg total protein) was reconstituted
to 1 ml PBS2+ (PBS with 0.9 mM CaCl2, 0.5 mM MgCl2) containing
1% BSA, 0.1 mM PMSF, 1 mM Na3VO4. Samples were incubated
with 0.5 mg IgGs and 30 ml of mMACS Protein A or G MicroBeads (Mil-
tenyi Biotec) on ice for 1 hr. The samples were then loaded onto
MACS Separation columns, washed, and eluted. The eluents were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) and immunoblotting. These experiments were
repeated at least three times with the same result.
NGF Binding and Internalization in Synaptosomes
These studies were conducted essentially as described (Cooper
et al., 2001, see also Supplemental Experimental Procedures). The
data report the results of the following number of mice (non-Tg =
4, APPSwe = 4, APPSwe/PS1A246E = 4, PS1A246E = 4) at age 18 to 24
months.
App and NGF mRNA Measurements
Eighteen-month-old 2N, Ts1Cje, and Ts65Dn mice were deeply
anesthetized with sodium pentobarbital (200 mg/kg i.p.), trans-
cardially perfused with ice-cold normal saline and studied for




Ts65Dn and Ts1Cje Mice and Their 2N Controls. Ts65Dn and 2N
mice were euthanized with sodium pentobarbital (200 mg/kg i.p.)
Neuron
40(Abbott Laboratories, North Chicago, IL). The brains were quickly re-
moved and several brain regions, including hippocampus, were dis-
sected on ice prior to storage at280ºC. Brain samples were homog-
enized in HEPES-buffered saline (50 mM HEPES [pH 7.4], 0.15 M
NaCl, and 5 mM EDTA containing a protease inhibitor cocktail;
Sigma Chemical Company) and centrifuged at 2500 3 g for 10 min
and supernatants were collected for further analysis. Western blots
were used to determine the levels of FL-App and its App-CTF (C-83
plus C-99) after loading 2, 3, and 4.5 mg of the extract onto SDS-
PAGE gels (BioRad Criterion 10%–20%) (Sambamurti et al., 1992).
APP was detected using a rabbit antibody to the C-terminal 20 res-
idues APP (O443) as described previously (Pinnix et al., 2001). Im-
ages from multiple repeats of each sample were run on independent
gels and scanned images were quantified using ImageQuant soft-
ware (Amersham Corporation, Piscataway, NJ). To avoid the varia-
tion due to differences in exposure of films, we normalized the
values for each gel using the average of all quantified bands. Eleven-
to twelve-month-old 2N, Ts1Cje, and Ts65Dn mice were used in the
App protein studies.
Ts65Dn:App+/+/2 and Ts65Dn:App+/+/+ Mice and Their 2N Con-
trols. The cerebral cortex was homogenized in 0.2% diethylamine
(DEA/50 mM NaCl) and processed as described (Petanceska et al.,
2000). Samples were solubilized in 2% SDS/PBS containing 7 mg/
ml aprotinin, 1 mg/ml leupeptin, and 1 mM phenylmethylsulphonyl-
fluoride, then sonicated and boiled. The protein concentrations
were determined using a bicinchoninic acid (BCA) protein assay
kit (Pierce, Rockford, IL). Twenty-five micrograms total proteins
were loaded per lane onto 4%–20% Tris-Glycine gels (Invitrogen,
Carlsbad, CA) and separated by electrophoresis at 100 volts for 1
hr. APP was detected by Western blotting using a polyclonal anti-
body CT695 (Zymed, South San Francisco, CA) directed against
the C terminus of human APP. Immunoblots were scanned using
an Agfa Duoscan f40 scanner (Germany) and analyzed by the NIH
Image (Bethesda, MD). Mice at 16 months of age were used for
this study.
Adaptor Proteins
Synaptosomes from the hippocampi of Ts65Dn and 2N mice were
prepared as described above. The protein levels for dynein interme-
diate chain (DIC) (Santa Cruz Biotechnology), p150Glued, and p50
(both from BD, Franklin Lakes, NJ), were examined using SDS/
PAGE and Western blotting. Six-month-old mice (2N and Ts65Dn)
were used; each experimental group, of which there were two,
was comprised of three mice (2N, n = 3; Ts65Dn, n = 3).
Ab ELISA Measurements
Eighteen-month-old 2N and Ts65Dn mice were euthanized and
brains were removed and dissected on ice prior to freezing in liquid
nitrogen. Brain samples were studied for Ab40 and Ab42 levels as
described in the Supplemental Experimental Procedures.
NGF ELISA Measurements
Ts1Cje and 2N mice were euthanized with CO2 and their brains were
removed. The hippocampus was dissected and immediately frozen
on dry ice and stored at280ºC. Samples were homogenized and an-
alyzed for NGF protein using an ELISA from Chemicon, as de-
scribed, using mouse NGF as the standard (Cooper et al., 2001).
Twenty-month-old 2N and Ts1Cje mice were used for this study.
Statistics
Statistica 6 (Tulsa, OK) was used for all analyses, except for NGF
transport studies, for which Microsoft Excel was used. Student’s
t test was used for all transport studies. Data on BFCN cell size
and number and NGF transport were analyzed using Kruskal Wallis
ANOVA and Mann-Whitney U tests. A value of p < 0.05 was consid-
ered statistically significant.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/51/1/29/DC1/.
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